We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Diabetic Foot Ulcer

A prospective, randomized, controlled study comparing Apligraf® plus conventional therapy (debridement, saline dressings, total off-loading) to conventional therapy alone.

Study Design
Patient Demographics
  • 208 patients enrolled with diabetic foot ulcers
    • 67 with type 1 diabetes; 139 with type 2 diabetes; 2 not specified
  • Study excluded patients who exhibited rapid healing (>30% closure from day - 7 to day 0)
Ulcer Charactersitics
  • All patients had ulcers on the plantar surface of the foot
  • Mean ulcer size: 2.97 cm2 and 2.83 cm2 in the Apligraf and Control group, respectively
  • Mean duration: 12 months in the Apligraf group and 11 months in the Control group
  • All patients used either crutches or a wheelchair for the first 6 weeks, followed by customized pressure-relieving footwear for at least 4 weeks postclosure